News & Updates

New drug applications approved by US FDA as of 16-30 November 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The selective agonist of sphingosine-1-phosphate receptor-1 (S1PR1), proximod, appears to be well tolerated and helps reduce blood lymphocyte count in patients with rheumatoid arthritis (RA), according to a phase I study.

Achieving target serum urate levels with urate-lowering therapy (ULT) does not appear to worsen kidney function in patients with gout and chronic kidney disease (CKD), as shown in a study.

Intravenous (IV) secukinumab appears beneficial in the treatment of adults with active axial spondyloarthritis (axSpA), with improvements seen across disease activity, physical function, quality of life, and sleep measures, according to the results of the phase III INVIGORATE-1 trial.

In the treatment of adults with chronic low back pain (LBP), virtual yoga classes are feasible, reducing pain intensity and improving sleep, according to a study.

Compared with conventional therapies, exposure to tumour necrosis factor (TNF) inhibitors is associated with increased risk of inflammatory central nervous system (CNS) diseases, irrespective of background autoimmune disease or TNF inhibitor type, a recent meta-analysis has found.

Individuals who have recently received a diagnosis of gout face an increased risk of cardiovascular events within 30 days of the index diagnosis, according to a study.